increased by 14.28% Net Profit amounted to THB 61.32 million increased by 60.83% Statement of Comprehensive Income (Consolidated) Q2/2023 Q2/2024 Increase (Decrease) %YoY Amount % Amount % Sales and services
management. Based on the Company's financial statements for the year ended December 31st, 2019 Upon considering the Company’s Specific Business Financial Statement for the year ended December 31st, 2019, it
resolutions as following: (1) Approved the Balance Sheet and the Profits and Loss Statement as of 31 December 2019 (2) Approved the dividend payment from the company’s performance of the period 1 July – 31
No. 2/2018 of Bangkok Dec-con Public Company Limited (the “Company” or “BKD”), which was convened on Feburary 22, 2018 resolved to approve the acquisition of the Project, Production and distribution of
. Disclose a reasonably itemized statement of the major categories of expenses incurred in connection with the issuance and distribution of the debt securities to be offered. (in absolute terms and as a
, international sales grew 2.3%, driven by growth from Myanmar market (+9.1% YoY). Financial Performance for Q3’18 and 9M18 Income Statement Summary Unit: THB million Q3’18 Q3’17 % YoY 9M18 9M17 % YoY Total
decreasing from the expense management of domestic customer by reduce some distribution channels that could not well generate income to other distribution channels instead. In this regard, the Company could
sales staffs, advertising media fee for product promotion, distribution fee paid to Zuellig Pharma Ltd. under the Distribution Agreement and compensation for distribution of company’ s products in the
Republic of Vietnam; “registration statement” means the registration statement for offer for sale of securities issued by a foreign company; “electronic information” means the information created